Fig. 3

TRIM59 accelerated the proliferation of PASMCs. A After TRIM59 over-expression, the mRNA level of TRIM59 was determined by qPCR. B Western blot was performed to detect the protein level of TRIM59 after TRIM59 over-expression. C After TRIM59 over-expression, the cell viability of PASMCs with TRIM59 over-expression was evaluated by CCK-8 assay. D The proliferation of PASMCs was assessed by EdU incorporation assay. Magnification: × 200. White arrows indicated EdU-positive cells. E Imunofluorescence staining with Ki-67 antibody was conducted after TRIM59 over-expression. Magnification: × 200. White arrows indicated Ki-67-positive cells. F PASMCs with TRIM59 silencing were treated under a hypoxic condition, then the mRNA level of TRIM59 was determined by qPCR. G The level of TRIM59 was determined by western blot after indicated treatment. H CCK-8 assay was conducted in cells with indicated treatment. I EdU incorporation assay was performed to assess the proliferation of PASMC after indicated treatment. Magnification: × 200. White arrows indicated EdU-positive cells. J Ki-67 inofluorescence staining was conducted after TRIM59 over-expression. Magnification: × 200. White arrows indicated Ki-67-positive cells. *p < 0.05